Pioglitazone and metformin
Abstract
Pioglitazone and metformin have both proven safe and efficacious in the treatment of type 2 diabetes. Their combination into a single tablet seems logical. This article reviews the data that are available for this combination. Because the tablets are not currently widely available, the review examines some aspects of the effects of both agents separately and in the few trials where they have been administered concurrently, though not as a single pharmaceutical preparation. Based on this evidence, the combination appears therapeutically efficacious and clinically safe. The side effects are not multiplicative and reflect those predictable from monotherapy with either agent.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.